Present Moment: High-Yield Investment Opportunities With a Triple Benefit

Sanofi, the fifth-largest international drugmaker, and Comcast Corporation, a telecom and entertainment powerhouse, are currently thriving in their respective industries.

Sanofi's stock is trading at a forward 12-month P/E ratio of 10.3, which is below its 10-year average P/E ratio of 13.4. This undervalued position could present an opportunity for investors, as the FAST Graphs analyst consensus projects EPS to grow by 10.2% annually through 2027, off a 2024 base of $3.70. If Sanofi returns to fair value and lives up to these growth expectations, it could have a 31% upside through September 2026.

Sanofi's market cap stands at $122 billion, making it one of the larger pharmaceutical companies in the world. The company's success is evident in the first half of 2025, where all of its key products logged growth, with a 20%+ uptick in Dupixent revenue leading the charge. As of Q2 2025, Sanofi had five drugs that were either blockbusters or on their way to becoming so, including Dupixent, Lantus and Toujeo insulins, Altuviiio hemophilia A therapy, polio/pertussis and meningitis, travel, and endemic vaccines. Sanofi's pipeline is robust, with 82 clinical-stage projects, 30 of which are in either phase 3 clinical trials or the registration phase.

Sanofi's financial health is also strong, with a dividend yield of 4.4%, which is appealing, and the payout ratio expected to be in the low-50% range in 2025.

On the other hand, Comcast, the largest Internet provider in the U.S., is trading at a forward 12-month P/E ratio of 7.6. In 2024, the company generated $81.3 billion in revenue and $32.8 billion in adjusted EBITDA. Comcast's Content & Experiences businesses, which include Peacock, Universal Studios, NBC News, and theme parks, generated another $45.1 billion in revenue in 2024. Comcast's payout ratio is set to be in the low-30% range for 2025, and its dividend yield stands at 3.9%, about triple the S&P 500 index's 1.2% yield.

Comcast's financial strength is underscored by its A- credit rating from S&P with a stable outlook. The company has more than 51 million customers on its network as of Q2 2025. If Comcast matches the growth consensus and reverts to fair value, it could have an 87% upside by the end of September 2026.

AES Corporation, a major hybrid (regulated and non-regulated) utility, also presents an interesting opportunity. AES owns and manages $47 billion in assets as of December 31st, 2024. AES's stock is priced at a forward 12-month P/E ratio of 6.1. The company had $12.3 billion in total revenue in 2024 and a BBB- credit rating from S&P with a stable outlook. AES has a market-leading position in signed agreements with data center customers (11 GW), and it had 12 GW of backlog as of Q2 2025, with about half expected to be completed by the end of 2027. AES's 5.2% dividend yield is rather generous.

While the search results do not provide information about which institution Kody mentioned in a past list article that is related to Wide Moat Research's preference for distinguishing large dividends, it's clear that both Sanofi and Comcast offer attractive dividend yields for investors seeking income. However, as with any investment, it's essential to conduct thorough research and consider individual risk tolerance before making decisions.